adherence to topical ocular hypotensives and application of health belief model among glaucoma patients visiting a tertiary care hospital in coastal Karnataka, India
Sir, The health belief model (HBM) is a classical behavior theory that explains health behaviors. It contains cognitive constructs (including perceived susceptibility, benefits, barrier; cues to action, and self-efficacy) that predict why people take actions to control their illnesses. [1] [2] [3] [4] Applicability of HBM in glaucoma medication adherence has not been explored fully among the Indian population. An attempt was made to discover this using a semi-structured, pretested, interview schedule based on HBM.
The following HBM-related factors [ Fig. 1 ] were associated with low adherence: poor understanding of the disease and importance of medications, lack of self-efficacy (individual belief regarding their capabilities to carry out a specific task to achieve a desired outcome), [5] side effects of glaucoma medications, additional medications for other comorbidities, lack of family and social support, and no follow-up visit in the past 6 months.
By understanding the cognitive constructs of poor adherence behavior, we can circumvent them by formulating a targeted approach. The physician can play a key role by educating the patient about the nature of the disease, its prognosis with emphasis on the impact of medication and their expected side effects. Patients have to be trained to self-administer the drops. The family of the patient needs to be involved in the treatment plan.
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Comment on: A rare case of unilateral diffuse melanocytic proliferation
Sir, We read with great interest the case report by Ayachit et al. [1] describing unilateral presentation of diffuse uveal melanocytic proliferation (DUMP) syndrome. The authors must be complemented on immaculate documentation of this rare case with multimodal imaging.
However, a couple of areas need clarification. Oral tamoxifen was started for this patient with biopsy-proven metastatic breast cancer as the tumor had estrogen and progesterone receptor (PR) positivity. Tamoxifen has been shown to be the treatment of choice for postmenopausal females with PR-positive metastatic breast cancer. [2] How did the primary site respond to chemotherapy? If the tumor reduced in size after chemotherapy, is it not possible that the paraneoplastic syndrome associated with it would also reduce in severity/intensity? Second, DUMP is a paraneoplastic phenomenon and hence to institute intravitreal bevacizumab (IVB) therapy for this entity defies logic. Furthermore, regression shown by the authors on optical coherence tomography is after 2 months after starting tamoxifen and IVB. The authors site the report by Lin et al., in which the efficacy of IVB for choroidal metastasis due to colon cancer is highlighted. [3] DUMP is distinct from metastasis and occurs due to distant effect of the primary tumor. To ascribe the resolution of subretinal fluid and improvement of visual acuity solely to IVB would be incorrect, especially when it is known that even plasmapheresis/steroids do not work in most cases of DUMP. [4, 5] Financial support and sponsorship Nil.
